Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.IGI Laboratories has submitted its seventh abbreviated new drug application (ANDA) to the US Food and Drug Administration (FDA) of 2015, which brings the company's total number of ANDA submissions now pending at the FDA to twenty-nine.
Subscribe to our email newsletter
IGI Laboratories president and CEO Jason Grenfell-Gardner said: "We believe our current pipeline of twenty-nine submissions, exclusive of our four partnered submissions, pending approval by the FDA now has a combined addressable market of over $1.4 billion based on July 2015 data from IMS Health."